Printer Friendly


 FRANKLIN LAKES, N.J., and INDIANAPOLIS, Sept. 29 /PRNewswire/ -- A National Institutes of Health (NIH) study on diabetes is expected to change how patients manage the disease and how three healthcare companies market their products. The companies -- manufacturers of medical supplies, blood glucose monitors and insulin -- will launch a long-term collaboration called the Partnership to Advance Care and Education in Diabetes, or P.A.C.E. Diabetes.
 Becton Dickinson and Company (B-D) (NYSE: BDX), Boehringer Mannheim Corporation (BMC) (privately held) and Eli Lilly and Company (Lilly) (NYSE: LLY) will combine resources on educational initiatives to improve the standard of diabetes care and the quality of life for people with diabetes. The companies aim to improve the quality of information and service to health professionals and patients and better control healthcare costs.
 "Until now, each company has maintained separate educational and service efforts. Just as the NIH-sponsored trial shows that better control of diabetes requires a team approach, P.A.C.E. unites industry leaders that have operated traditionally in separate spheres," noted Robert Singley, director of marketing, Becton Dickinson and Company. "This alliance is an opportunity to improve diabetes management in the United States by getting the word out faster and to more people about new advances, such as the Diabetes Control and Complications Trial results," he added.
 According to the American Diabetes Association, many of America's 6.5 million people diagnosed with diabetes are at risk for developing serious complications, such as vascular and kidney disease, and blindness. The cost of diabetes exacts a heavy toll on patients physically and the nation economically. According to a new report from the American Diabetes Association, the U.S. healthcare system spends an estimated $91.8 billion annually in diabetes patient care.
 "We are pleased that P.A.C.E. Diabetes is supporting and complementing our efforts to reach health professionals, people with diabetes and the lay public with information that is vital to improving the long-term health and quality of life for people with diabetes," said James Gavin III, M.D., Ph.D., president American Diabetes Association. "Together we can provide education about the risks of complications associated with the disease which could help simplify and improve current diabetes management," he added.
 Current P.A.C.E. Diabetes initiatives include:
 -- Support of National Diabetes Associations -- distribution of patient information and physician treatment guidelines based on the 10- year, National Institutes of Health-sponsored Diabetes Control and Complications Trial (DCCT);
 -- Educational Materials for Patients, Physicians and Educators -- development and distribution of targeted educational materials based on the DCCT results;
 -- Pharmacy Counselor Program -- development and distribution of educational materials, including brochures, posters and patient handouts, targeted to pharmacists for use as a counseling aid with their diabetes patients.
 In addition, members of P.A.C.E. Diabetes have joined forces to launch a new consumer educational program called the Take Charge Kit, to help educate newly diagnosed insulin-using patients. This patient care kit is designed to introduce patients to successful diabetes management by combining educational materials and products from each alliance member. The kit is currently available to patients through their healthcare professionals.
 "As leaders dedicated to high quality diabetes care, we hope this educational initiative and future efforts like it will help empower people with diabetes to develop and maintain the best possible personal regimen for themselves," said Mark Williams, vice president of marketing, Boehringer Mannheim Corporation.
 DCCT, the longest and largest study of its kind, now more than ever demonstrates the need to bring blood glucose concentrations to near- normal levels through intensive therapy. Utilizing intensive diabetes therapy can significantly reduce the complications of diabetes such as blindness, kidney disease and peripheral limb nerve damage, leading to amputation. Initial results presented at the American Diabetes Association Annual Meeting strongly support intensive therapy for insulin-dependent diabetes patients (Type I) to improve their long-term outcomes. Many non-insulin-dependent diabetes patients (Type II) might also benefit from intensive diabetes management, according to the American Diabetes Association. Complete study results are expected to be published in a leading medical journal shortly.
 Approximately 13 million Americans have diabetes and an estimated 6.5 million have not been diagnosed and are not receiving medical care. P.A.C.E. Diabetes recognized this public health issue and believes an urgent need exists to educate the public on the impact of diabetes.
 "The initiative among B-D, BMC and Lilly represents a significant step forward in improving diabetes care for the patient, family members and healthcare professionals," noted John Holcombe, M.D., clinical research physician for United States Diabetes Care, Eli Lilly and Company. "In placing an emphasis on education, we hope to expand our reach to those who are undiagnosed or are in poor diabetes control and remain at risk," he added.
 Becton Dickinson and Company manufactures and sells a broad range of medical supplies and devices and diagnostic systems for use by healthcare professionals, medical research institutions and the general public. B-D's insulin delivery devices are considered the "gold standard" for people with diabetes who are insulin dependent.
 Boehringer Mannheim Corporation is a leading supplier of chemical reagents and instruments for testing and monitoring body chemistries and a major supplier of natural and synthetic substances for research in healthcare and life sciences. The company markets the Accu-Chek(R) line of blood glucose monitoring systems and is the only diagnostic company that has provided instruments for screening, diagnosis and monitoring of illness from the hospital to the home setting.
 Eli Lilly and Company is a global research-based corporation that develops, manufactures and markets pharmaceuticals, medical devices and diagnostic products. For more than 70 years, Lilly has been providing products for patients with diabetes.
 Since 1923 when Lilly pioneered the first mass produced animal- source insulin, Lilly has been a world leader in diabetes care. Ten years ago, Lilly introduced Humulin(R) (human insulin /recombinant DNA origin/) -- an insulin exactly like that produced by the human body -- and the world's first commercial product of recombinant DNA technology. Today, Humulin (the only insulin manufactured in the United States) is used by more than 2 million patients worldwide every day.
 -0- 9/29/93
 /CONTACT: Robert Singley of Becton Dickinson and Company, 201-847-6545; Mark Williams of Boehringer Mannheim Corporation, 317-845-2348; or Edward West of Eli Lilly and Company, 317-276-3655/

CO: Becton Dickinson and Company; Boehringer Mannheim Corporation;
 Eli Lilly and Company; National Institutes of Health ST: New Jersey, Indiana IN: MTC SU: PDT

CK-LG -- NY001 -- 6690 09/29/93 09:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters